Despite topline pressure, Genomma Lab delivered a resilient year-end 23.4% EBITDA margin and maintained a healthy 107-day cash-conversion cycle, underscoring the strength of our business fundamentals, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results